

A Grzybowski^{1,2} and A Justynska³

¹Department of Ophthalmology, Poznań City Hospital, Poznań, Poland

²Department of Ophthalmology, University of Warmia and Mazury, Olsztyn, Poland

³Department of Ophthalmology, L Rydygier's Specialist Hospital in Cracow, Cracow, Poland
E-mail: ae.grzybowski@gmail.com

Eye (2013) **27**, 1418–1419; doi:10.1038/eye.2013.208;
published online 20 September 2013

Sir,

Response to Grzybowski and Justynska

We thank Dr Grzybowski and Justynska¹ for their interest in our article.

In response to their comments on our report² we acknowledge the inadvertent omission of articles that emphasize the occurrence of inflammatory-marker-negative disease seen in giant cell arteritis (GCA). Unfortunately some papers referred to were not published at the time of writing.^{3,4} The table provided by Dr Grzybowski and Justynska highlights some important articles, some of which were referenced in our original report⁵ and others which were summarized by key articles referenced.^{6,7,8}

Dr Grzybowski and Justynska remark that typical features commonly associated with GCA were not presented in our case. However, the patient we described was indeed unique in that the patient did not display symptoms usually found in GCA other than AION-induced loss of vision and corresponding RAPD in a patient with known polymyalgia rheumatica. These features were described in our report. We fully agree that scrutinizing the clinical picture is critical in the diagnosis of GCA but would like to emphasize that this is exactly what we did. We specifically looked at the clinical presentation including increased pre-test probability due

Table 1 Summary of current literature—revised and updated according to comments by Grzybowski and Justynska

	ESR-negative disease	CRP-negative disease	ESR- and CRP-negative disease
Pariikh <i>et al</i> ⁵	14.3%	1.7%	0.8%
Ellis and Ralston ⁹	22.5% at initial presentation		
Weintraub ¹⁰	1 case report		
Levy <i>et al</i> ²		1 case report	
Laria <i>et al</i> ⁴			1 case report
Kermani <i>et al</i> ³			4%
Yoeruek <i>et al</i> ¹¹			1 case report
Raja <i>et al</i> ¹²			1 case report
Man and Dayan ¹³			1 case report
Poole <i>et al</i> ¹⁴			1 case report

to ethnicity in order to come to the conclusion that the negative CRP needed to be ignored!

We are very grateful for the additional case reports and have integrated them into our original table, thereby giving a more detailed understanding of inflammatory-marker-negative disease (Table 1).

Conflict of interest

The authors declare no conflict of interest.

References

- Grzybowski A, Justynska A. Giant cell arteritis with normal ESR and/or CRP is rare, but not unique! *Eye* 2013; **27**: 1418–1419.
- Levy SL, Bull AD, Nestel AR. How common is inflammatory marker-negative disease in giant cell arteritis? *Eye* 2013; **27**: 106–108.
- Kermani TA, Schmidt J, Crowson CS, Ytterberg SR, Hunder GG, Matteson EL *et al*. Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. *Semin Arthritis Rheum* 2012; **41**: 866–871.
- Laria A, Zoli A, Bocci M, Castri F, Federico F, Ferraccioli GF. Systematic review of the literature and a case report informing biopsy-proven giant cell arteritis (GCA) with normal C-reactive protein. *Clin Rheumatol* 2012; **31**: 1389–1393.
- Pariikh M, Miller NR, Lee AG, Savino PJ, Vacarezza MN, Cornblath W *et al*. Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. *Ophthalmology* 2006; **113**(10): 1842–1845.
- Rahman W, Rahman FZ. Giant cell (temporal) arteritis: an overview and update. *Surv Ophthalmol* 2005; **50**: 415–428.
- Wong RL, Korn JH. Temporal arteritis without an elevated erythrocyte sedimentation rate. Case report and review of the literature. *Am J Med* 1986; **80**: 959–964.
- Myklebust G, Gran JT. A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. *Br J Rheumatol* 1996; **35**: 1161–1168.
- Ellis ME, Ralston S. The ESR in the diagnosis and management of the polymyalgia rheumatica/giant cell arteritis syndrome. *Ann Rheum Dis* 1983; **42**: 168–170.
- Weintraub MI. Temporal arteritis. *Arch Neurol* 1978; **35**: 183.
- Yoeruek E, Szurman P, Tatar O, Weckerle P, Wilhelm H. Anterior ischemic optic neuropathy due to giant cell arteritis with normal inflammatory markers. *Graefes Arch Clin Exp Ophthalmol* 2008; **246**(6): 913–915.
- Raja MK, Proulx AA, Allen LH. Giant cell arteritis presenting with aortic aneurysm, normal erythrocyte sedimentation rate, and normal C-reactive protein. *Can J Ophthalmol* 2007; **42**: 136–137.
- Man P, Dayan MR. Giant cell arteritis with normal inflammatory markers. *Acta Ophthalmol Scand* 2007; **85**: 460.
- Poole TR, Graham EM, Lucas SB. Giant cell arteritis with a normal ESR and CRP. *Eye* 2003; **17**(1): 92–93.

SL Levy¹, AD Bull² and AR Nestel³

¹Royal Eye Infirmary, Plymouth, UK

²Histopathology Department, North Devon District Hospital, Barnstaple, UK

³Ophthalmology Department, North Devon District Hospital, Barnstaple, UK
E-mail: sarahfoster@doctors.org.uk

Eye (2013) 27, 1419–1420; doi:10.1038/eye.2013.210;
published online 20 September 2013

Sir,
**Is the mechanism of ‘poppers maculopathy’
photic injury?**

I read with interest the excellent series by Davies *et al*,¹ describing maculopathy in patients using ‘poppers.’ Together with two recent series from France,^{2,3} their report provides important evidence for an association between abuse of alkyl nitrite compounds and specific, sub-foveal changes. Whether this association is causal remains to be determined, and Davies *et al* suggest causality is likely.

What I find most striking about the cases attributed to ‘poppers maculopathy’ in the Davies series (and which is consistent with the two series from France) is the SD-OCT imaging—which has an uncanny resemblance to photic maculopathy (Figure 1). In both ‘poppers maculopathy’ and photic maculopathy, there is focal disruption of the IS-OS junction centred at the fovea.^{1–4} Moreover, the size, shape, echogenicity, and temporal evolution of the SD-OCT lesions appear indistinguishable in the two conditions. Patients also present with the same symptoms (scotoma, reduced vision, and phosphenes) and have the same slit-lamp

findings (a pale yellow foveal lesion).^{1–4} Indeed, it appears that in people using poppers, the two conditions can only be reliably distinguished by eliciting a history of excess light exposure and not by clinical features.

Unfortunately, Davies *et al*¹ did not report to what extent excessive light exposure was specifically queried in their patients. In the two French series,^{2,3} all patients ‘denied staring at bright lights’—yet how reliable is their history? Poppers are frequently combined with psychotropic drugs and alcohol, which can alter consciousness and memory, potentially making history unreliable.⁵ Poppers themselves can cause transient visual hallucinations and heightened sensory perception⁵—effects that are known to increase light-gazing behaviour in other recreational drugs such as LSD.⁶ Poppers are frequently used in raves, where bright strobe lights and lasers are common.

Given the points discussed, it should be crucial when considering the diagnosis of ‘poppers maculopathy’ to document a thorough history of the patient’s drug behaviour and light exposure. Do they take multiple drugs? Do they hallucinate or experience altered consciousness? Are they ever entranced by bright lights, candles, or the sun?

The endemic use of poppers⁴ and the mere handful of reports of maculopathy suggests that compounding factors or susceptibilities may be involved. It is not inconceivable that ‘poppers maculopathy’ represents a sub-group of patients who have unrecognised photic injury. If poppers maculopathy is indeed a distinct entity, then the remarkable ultrastructural similarity with photic injury suggests that the two conditions share a common




Figure 1 A comparison of SD-OCT images in (a) ‘poppers maculopathy’ as presented in Case 2 of Davies *et al*¹ with (b) photic retinopathy in a 30-year-old male who presented to my clinic 2 weeks after sun-gazing. Notice the similarity in location, size, shape, and echogenicity of the respective lesions in the IS-OS junction.